You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 7,871,988

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,871,988

Title:	Nanoparticles for protein drug delivery
Abstract:	The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:	12/321,855
Patent Claims:	1. A method of reducing inflammatory response caused by a tumor necrosis factor (TNF) in an animal subject, the method comprising orally administering nanoparticles consisted of a TNF inhibitor, positively charged chitosan, and a negatively charged substrate, wherein said negatively charged substrate is at least partially reacted with a portion of said positively charged chitosan. 2. The method of claim 1, wherein the inhibitor is a monoclonal antibody. 3. The method of claim 1, wherein the inhibitor is infliximab. 4. The method of claim 1, wherein the inhibitor adalimumab. 5. The method of claim 1, wherein the inhibitor is a circulating receptor fusion protein. 6. The method of claim 1, wherein the inhibitor is etanercept. 7. The method of claim 1, wherein the chitosan has a molecular weight about 80 kDa or less. 8. The method of claim 1, wherein said negatively charged substrate is .gamma.-PGA, .alpha.-PGA, derivatives of PGA, or salts of PGA. 9. The method of claim 1, wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers. 10. The method of claim 1, wherein the chitosan is N-trimethyl chitosan, EDTA-chitosan, or chitosan derivatives. 11. The method of claim 1, wherein said nanoparticles further comprise a permeation enhancer. 12. The method of claim 11, wherein said permeation enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, and phosphate esters. 13. The method of claim 1, wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form. 14. The method of claim 1, wherein said nanoparticles are formed via a simple and mild ionic-gelation method. 15. The method of claim 1, wherein said nanoparticles further comprise zinc, magnesium sulfate or sodium tripolyphosphate (TPP). 16. The method of claim 1, wherein at least a shell portion of said nanoparticles is crosslinked. 17. The method of claim 1, wherein said nanoparticles are encapsulated in capsules. 18. The method of claim 17, wherein said capsules are treated with an enteric coating. 19. The method of claim 17, wherein said capsules further comprise a permeation enhancer. 20. The method of claim 17, wherein said capsules further comprise a solubilizer or pharmacopoeial excipients.

Details for Patent 7,871,988

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2025-01-04
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2025-01-04
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2025-01-04
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2025-01-04
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2025-01-04
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2025-01-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.